CoChat
Sign Up
Cited by 23

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Applications and Efficacy of Iron Oxide Nanoparticles in the Treatment of Brain Tumors

Varalli, London, Berlet, Reed, Abenojar, EC, McDaid, John, Gascoigne, David A., Bailes, Julian, Aksenov, Daniil P.·2025·Pharmaceutics
DOI 10.3390/pharmaceutics17040499PMC PMC12030199
Open this paper in CoChat — free account

Abstract

Cancers of the central nervous system are particularly difficult to treat due to a variety of factors. Surgical approaches are impeded by the skull—an issue which is compounded by the severity of possible harm that can result from damage to the parenchymal tissue. As a result, chemotherapeutic agents have been the standard of care for brain tumors. While some drugs can be effective on a case-by-case basis, there remains a critical need to improve the efficacy of chemotherapeutic agents for neurological cancers. Recently, advances in iron oxide nanoparticle research have highlighted how their unique properties could be leveraged to address the shortcomings of conventional therapeutics. Iron oxide nanoparticles combine the advantages of good biocompatibility, magnetic susceptibility, and functionalization via a range of coating techniques. Thus, iron oxide nanoparticles could be used in both the imaging of brain cancers with magnetic resonance imaging, as well as acting as trafficking vehicles across the blood–brain barrier for targeted drug delivery. Moreover, their ability to support minimally invasive therapies such as magnetic hyperthermia makes them particularly appealing for neuro-oncological applications, where precision and safety are paramount. In this review, we will outline the application of iron oxide nanoparticles in various clinical settings including imaging and drug delivery paradigms. Importantly, this review presents a novel approach of combining surface engineering and internal magnetic targeting for deep-seated brain tumors, proposing the surgical implantation of internal magnets as a next-generation strategy to overcome the limitations of external magnetic fields.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/pharmaceutics17040499

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Conceptual overview of IONP synthesis methods (center), their key functional applications (right), and corresponding clinical applications (left). Each synthesis route—co-precipitation, thermal decomposition, hydrothermal synthesis, and microemulsion—can be tailored to produce nanoparticles optimized for imaging, drug delivery, or magnetic hyperthermia. These functionalized IONPs can then be employed to treat superficial and deep-seated tumors, with ongoing research pointing to future directions for further clinical translation.
Figure 1 Conceptual overview of IONP synthesis methods (center), their key functional applications (right), and corresponding clinical applications (left). Each synthesis route—co-precipitation, thermal decomposition, hydrothermal synthesis, and microemulsion—can be tailored to produce nanoparticles optimized for imaging, drug delivery, or magnetic hyperthermia. These functionalized IONPs can then be employed to treat superficial and deep-seated tumors, with ongoing research pointing to future directions for further clinical translation.CC BY · PubMed Central
Figure 2 Conceptual design. Superficial brain tumor, treatable through external magnetization. Initial tumor mass shown in (A). Partial removal of the tumor through surgery, leaving residual cancerous cells due to the tumor’s irregular shape (B). After injecting IONPs, an external magnet is applied to attract nanoparticles to the tumor resection site (C). The localized IONPs then target residual cancer cells and potentially improve patient outcomes (D). Here, we recommend using IONPs synthetized with the co-precipitation method due to the simplicity and scalability of co-precipitation, which enables the rapid production of nanoparticles used in treatments involving external magnetic targeting.
Figure 2 Conceptual design. Superficial brain tumor, treatable through external magnetization. Initial tumor mass shown in (A). Partial removal of the tumor through surgery, leaving residual cancerous cells due to the tumor’s irregular shape (B). After injecting IONPs, an external magnet is applied to attract nanoparticles to the tumor resection site (C). The localized IONPs then target residual cancer cells and potentially improve patient outcomes (D). Here, we recommend using IONPs synthetized with the co-precipitation method due to the simplicity and scalability of co-precipitation, which enables the rapid production of nanoparticles used in treatments involving external magnetic targeting.CC BY · PubMed Central
Figure 3 Conceptual design. The proposed treatment for a deep tumor utilizing internal magnetization. Initial tumor mass (A). Partial removal of the tumor during surgery, leaving some residual cancerous tissue (B). Placement of a magnet in the tumor cavity during surgery (C). Following IONP injection, the internal magnet attracts the nanoparticles to the resection site, providing stable and continuous localization. This increases the likelihood of eradicating residual tumor cells and improving patient outcomes. (D) Here, we recommend using IONPs synthetized with thermal decomposition method due to the precision and monodispersity which thermal decomposition provides to optimize nanoparticle localization and retention in deep-seated tumor cavities.
Figure 3 Conceptual design. The proposed treatment for a deep tumor utilizing internal magnetization. Initial tumor mass (A). Partial removal of the tumor during surgery, leaving some residual cancerous tissue (B). Placement of a magnet in the tumor cavity during surgery (C). Following IONP injection, the internal magnet attracts the nanoparticles to the resection site, providing stable and continuous localization. This increases the likelihood of eradicating residual tumor cells and improving patient outcomes. (D) Here, we recommend using IONPs synthetized with thermal decomposition method due to the precision and monodispersity which thermal decomposition provides to optimize nanoparticle localization and retention in deep-seated tumor cavities.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 173

  1. Ostrom, 2019, CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016, Neuro Oncol., 21, v1, 10.1093/neuonc/noz150 · DOI
  2. Ostrom, 2021, CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018, Neuro Oncol., 23, iii1, 10.1093/neuonc/noab200 · DOI
  3. De Vleeschouwer, S. (2017). Current Standards of Care in Glioblastoma Therapy. Glioblastoma, Codon Publications. · DOI
  4. Maroon, 1995, Cryoprobe-assisted removal of spinal cord tumors: Technical note, Surg. Neurol., 43, 265, 10.1016/0090-3019(95)80011-5 · DOI
  5. Chang, 1983, Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study, Cancer, 52, 997, 10.1002/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO;2-2 · DOI
  6. Gilbert, 2013, Dose-dense temozolomide for newly diagnosed glioblastoma: A randomized phase III clinical trial, J. Clin. Oncol., 31, 4085, 10.1200/JCO.2013.49.6968 · DOI · Paper page
  7. Balana, 2020, A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01), Neuro Oncol., 22, 1851, 10.1093/neuonc/noaa107 · DOI
  8. Zanganeh, 2016, Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues, Nat. Nanotechnol., 11, 986, 10.1038/nnano.2016.168 · DOI · Paper page
  9. Ling, 2013, Chemical Design of Biocompatible Iron Oxide Nanoparticles for Medical Applications, Small, 9, 1450, 10.1002/smll.201202111 · DOI
  10. LaGrow, 2019, Unravelling the growth mechanism of the co-precipitation of iron oxide nanoparticles with the aid of synchrotron X-Ray diffraction in solution, Nanoscale, 11, 6620, 10.1039/C9NR00531E · DOI
  11. Ahn, 2012, Formation Pathways of Magnetite Nanoparticles by Coprecipitation Method, J. Phys. Chem. C, 116, 6069, 10.1021/jp211843g · DOI
  12. Khalil, 2015, Co-precipitation in aqueous solution synthesis of magnetite nanoparticles using iron (III) salts as precursors, Arab. J. Chem., 85, 279, 10.1016/j.arabjc.2015.02.008 · DOI
  13. Benamour, 2022, Synthesis of Fe3O4 Nanoparticles with Different Shapes Through a Co-Precipitation Method and Their Application, JOM, 74, 3531, 10.1007/s11837-022-05380-3 · DOI
  14. de Souza, T.C., Costa, A.F.S., Vinhas, G.M., and Sarubbo, L.A. (2023). Synthesis of Iron Oxides and Influence on Final Sizes and Distribution in Bacterial Cellulose Applications. Polymers, 15. · DOI
  15. Essyed, 2019, The effect of basic pH on the elaboration of ZnFe2O4 nanoparticles by co-precipitation method: Structural, magnetic and hyperthermia characterization, J. Magn. Magn. Mater., 478, 239, 10.1016/j.jmmm.2019.01.081 · DOI
  16. Rechtenbach, 2008, Synthesis and physical characterization of magnetite nanoparticles for biomedical applications, Mater. Chem. Phys., 110, 426, 10.1016/j.matchemphys.2008.02.037 · DOI
  17. Hauser, 2015, The effects of synthesis method on the physical and chemical properties of dextran coated iron oxide nanoparticles, Mater. Chem. Phys., 160, 177, 10.1016/j.matchemphys.2015.04.022 · DOI
  18. Basuki, 2014, A block copolymer-stabilized co-precipitation approach to magnetic iron oxide nanoparticles for potential use as MRI contrast agents, Polym. Chem., 5, 2611, 10.1039/C3PY01778H · DOI
  19. Chen, 2020, Moderate cooling coprecipitation for extremely small iron oxide as a pH dependent T1-MRI contrast agent, Nanoscale, 12, 5521, 10.1039/C9NR10397J · DOI
  20. Kayal, 2010, Doxorubicin loaded PVA coated iron oxide nanoparticles for targeted drug delivery, Mater. Sci. Eng. C, 30, 484, 10.1016/j.msec.2010.01.006 · DOI
  21. Predoi, 2008, Costache. Study of iron oxide nanoparticles coated with dextrin obtained by coprecipitation, J. Optoelectron. Adv. Mater., 10, 693
  22. Ebadi, M., Bullo, S., Buskara, K., Hussein, M.Z., Fakurazi, S., and Pastorin, G. (2020). Release of a liver anticancer drug, sorafenib from its PVA/LDH- and PEG/LDH-coated iron oxide nanoparticles for drug delivery applications. Sci. Rep., 10. · DOI
  23. Darwish, 2022, Functionalized iron oxide nanoparticles: Synthesis through ultrasonic-assisted co-precipitation and performance as hyperthermic agents for biomedical applications, Heliyon, 8, e09654, 10.1016/j.heliyon.2022.e09654 · DOI
  24. Darwish, M.S.A., Kim, H., Lee, H., Ryu, C., Lee, J.Y., and Yoon, J. (2019). Synthesis of Magnetic Ferrite Nanoparticles with High Hyperthermia Performance via a Controlled Co-Precipitation Method. Nanomaterials, 9. · DOI
  25. Ali, 2016, Synthesis, characterization, applications, and challenges of iron oxide nanoparticles, Nanotechnol. Sci. Appl., 9, 49, 10.2147/NSA.S99986 · DOI · Paper page
  26. Samrot, 2021, A review on synthesis, characterization and potential biological applications of superparamagnetic iron oxide nanoparticles, Curr. Res. Green Sustain. Chem., 4, 100042, 10.1016/j.crgsc.2020.100042 · DOI
  27. Dadfar, 2019, Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications, Adv. Drug Deliv. Rev., 138, 302, 10.1016/j.addr.2019.01.005 · DOI · Paper page
  28. Kwon, 2011, Formation Mechanisms of Uniform Nanocrystals via Hot-Injection and Heat-Up Methods, Small, 7, 2685, 10.1002/smll.201002022 · DOI
  29. Turcheniuk, 2013, Recent advances in surface chemistry strategies for the fabrication of functional iron oxide based magnetic nanoparticles, Nanoscale, 5, 10729, 10.1039/c3nr04131j · DOI
  30. Hao, 2010, Synthesis, Functionalization, and Biomedical Applications of Multifunctional Magnetic Nanoparticles, Adv. Mater., 22, 2729, 10.1002/adma.201000260 · DOI
  31. Rezaei, 2024, Magnetic Nanoparticles: A Review on Synthesis, Characterization, Functionalization, and Biomedical Applications, Small, 20, 2304848, 10.1002/smll.202304848 · DOI
  32. Montiel Schneider, M.G., Martín, M.J., Otarola, J., Vakarelska, E., Simeonov, V., Lassalle, V., and Nedyalkova, M. (2022). Biomedical Applications of Iron Oxide Nanoparticles: Current Insights Progress and Perspectives. Pharmaceutics, 14. · DOI
  33. Meng, Y.Q., Shi, Y.N., Zhu, Y.P., Liu, Y.Q., Gu, L.W., Liu, D.D., Ma, A., Xia, F., Guo, Q.Y., and Xu, C.C. (2024). Recent trends in preparation and biomedical applications of iron oxide nanoparticles. J. Nanobiotechnol., 22. · DOI
  34. Lu, 2007, Magnetic nanoparticles: Synthesis, protection, functionalization, and application, Angew. Chem. Int. Ed., 46, 1222, 10.1002/anie.200602866 · DOI
  35. Okeil, 2024, Tuning the Properties of Iron Oxide Nanoparticles in Thermal Decomposition Synthesis: A Comparative Study of the Influence of Temperature, Ligand Length and Ligand Concentration, Part. Part. Syst. Charact., 41, 2400059, 10.1002/ppsc.202400059 · DOI
  36. Park, 2004, Ultra-large-scale syntheses of monodisperse nanocrystals, Nat. Mater., 3, 891, 10.1038/nmat1251 · DOI · Paper page
  37. Unni, 2017, Thermal Decomposition Synthesis of Iron Oxide Nanoparticles with Diminished Magnetic Dead Layer by Controlled Addition of Oxygen, ACS Nano, 11, 2284, 10.1021/acsnano.7b00609 · DOI
  38. Ramimoghadam, 2014, Progress in electrochemical synthesis of magnetic iron oxide nanoparticles, J. Magn. Magn. Mater., 368, 207, 10.1016/j.jmmm.2014.05.015 · DOI · Paper page
  39. Sodipo, 2016, Recent advances in synthesis and surface modification of superparamagnetic iron oxide nanoparticles with silica, J. Magn. Magn. Mater., 416, 275, 10.1016/j.jmmm.2016.05.019 · DOI · Paper page
  40. Sathya, 2017, One-step microwave-assisted synthesis of water-dispersible Fe3O4 magnetic nanoclusters for hyperthermia applications, J. Magn. Magn. Mater., 439, 107, 10.1016/j.jmmm.2017.05.018 · DOI
  41. Aivazoglou, 2017, Microwave-assisted synthesis of iron oxide nanoparticles in biocompatible organic environment, AIP Adv., 8, 048201, 10.1063/1.4994057 · DOI
  42. Laurent, 2008, Magnetic iron oxide nanoparticles: Synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications, Chem. Rev., 108, 2064, 10.1021/cr068445e · DOI · Paper page
  43. Bilecka, 2010, Microwave chemistry for inorganic nanomaterials synthesis, Nanoscale, 2, 1358, 10.1039/b9nr00377k · DOI
  44. 2009, Practical Microwave Synthesis for Organic Chemists.Strategies, Instruments, and Protocols. Edited by C. Oliver Kappe, Doris Dallinger and Shaun Murphree, Angew. Chem. Int. Ed., 48, 2828, 10.1002/anie.200900791 · DOI
  45. Xiao, 2018, Microwave-assisted synthesis of nanocrystalline binary and ternary metal oxides, Int. Mater. Rev., 63, 341, 10.1080/09506608.2017.1402158 · DOI
  46. Ozel, 2015, Growth of Iron Oxide Nanoparticles by Hydrothermal Process: Effect of Reaction Parameters on the Nanoparticle Size, J. Supercond. Nov. Magn., 28, 823, 10.1007/s10948-014-2707-9 · DOI
  47. Ozel, 2015, Growth and characterizations of magnetic nanoparticles under hydrothermal conditions: Reaction time and temperature, J. Magn. Magn. Mater., 373, 213, 10.1016/j.jmmm.2014.02.072 · DOI
  48. Wegmann, M., and Scharr, M. (2018). Synthesis of Magnetic Iron Oxide Nanoparticles. Precision Medicine, Academic Press. · DOI
  49. Salvador, M., Gutiérrez, G., Noriega, S., Moyano, A., Blanco-López, M.C., and Matos, M. (2021). Microemulsion Synthesis of Superparamagnetic Nanoparticles for Bioapplications. Int. J. Mol. Sci., 22. · DOI
  50. Makovec, 2005, The synthesis of spinel–ferrite nanoparticles using precipitation in microemulsions for ferrofluid applications, J. Magn. Magn. Mater., 289, 32, 10.1016/j.jmmm.2004.11.010 · DOI
  51. Rivas, 2006, Synthesis of monodisperse maghemite nanoparticles by the microemulsion method, Colloids Surf. A Physicochem. Eng. Asp., 288, 44, 10.1016/j.colsurfa.2006.04.027 · DOI
  52. Darbandi, 2012, Nanoscale size effect on surface spin canting in iron oxide nanoparticles synthesized by the microemulsion method, J. Phys. D Appl. Phys., 45, 195001, 10.1088/0022-3727/45/19/195001 · DOI
  53. Overcast, 2021, Advanced imaging techniques for neuro-oncologic tumor diagnosis, with an emphasis on PET-MRI imaging of malignant brain tumors, Curr. Oncol. Rep., 23, 34, 10.1007/s11912-021-01020-2 · DOI
  54. Wagner, 2016, Pathophysiology of gadolinium-associated systemic fibrosis, Am. J. Physiol. Ren. Physiol., 311, F1, 10.1152/ajprenal.00166.2016 · DOI
  55. Quattrocchi, 2024, Ten years of gadolinium retention and deposition: ESMRMB-GREC looks backward and forward, Eur. Radiol., 34, 600
  56. Ringler, 2021, Gadolinium retention within multiple rat organs after intra-articular administration of gadolinium-based contrast agents, Skelet. Radiol., 50, 1419, 10.1007/s00256-020-03695-3 · DOI
  57. McDonald, 2015, Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging, Radiology, 275, 772, 10.1148/radiol.15150025 · DOI · Paper page
  58. Akai, 2021, Effects of Gadolinium Deposition in the Brain on Motor or Behavioral Function: A Mouse Model, Radiology, 301, 409, 10.1148/radiol.2021210892 · DOI
  59. Abujudeh, 2010, Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: Experience with 32,659 injections, AJR Am. J. Roentgenol., 194, 430, 10.2214/AJR.09.3099 · DOI
  60. Davies, J., Marino, M., Smith, A.P.L., Crowder, J.M., Larsen, M., Lowery, L., Castle, J., Hibberd, M.G., and Evans, P.M. (2021). Repeat and single dose administration of gadodiamide to rats to investigate concentration and location of gadolinium and the cell ultrastructure. Sci. Rep., 11. · DOI
  61. Kasten, A., Grüttner, C., Kühn, J.P., Bader, R., Pasold, J., and Frerich, B. (2014). Comparative in vitro study on magnetic iron oxide nanoparticles for MRI tracking of adipose tissue-derived progenitor cells. PLoS ONE, 9. · DOI
  62. McDonald, 2022, Neurologic Effects of Gadolinium Retention in the Brain after Gadolinium-based Contrast Agent Administration, Radiology, 302, 676, 10.1148/radiol.210559 · DOI
  63. Strzeminska, 2020, Long-Term Evaluation of Gadolinium Retention in Rat Brain After Single Injection of a Clinically Relevant Dose of Gadolinium-Based Contrast Agents, Investig. Radiol., 55, 138, 10.1097/RLI.0000000000000623 · DOI
  64. Marcus, M., Karni, M., Baranes, K., Levy, I., Alon, N., Margel, S., and Shefi, O. (2016). Iron oxide nanoparticles for neuronal cell applications: Uptake study and magnetic manipulations. J. Nanobiotechnol., 14. · DOI
  65. Cao, 2016, Effect of Renal Function on Gadolinium-Related Signal Increases on Unenhanced T1-Weighted Brain Magnetic Resonance Imaging, Investig. Radiol., 51, 677, 10.1097/RLI.0000000000000294 · DOI
  66. Foo, 2022, Alcohol solution strength preference predicts compulsive-like drinking behavior in rats, Alcohol. Clin. Exp. Res., 46, 1710, 10.1111/acer.14910 · DOI
  67. Roch, 1999, Theory of proton relaxation induced by superparamagnetic particles, J. Chem. Phys., 110, 5403, 10.1063/1.478435 · DOI
  68. Song, 2007, Labeling efficacy of superparamagnetic iron oxide nanoparticles to human neural stem cells: Comparison of ferumoxides, monocrystalline iron oxide, cross-linked iron oxide (CLIO)-NH2 and tat-CLIO, Korean J. Radiol., 8, 365, 10.3348/kjr.2007.8.5.365 · DOI
  69. Irrsack, 2021, Effects of Local Administration of Iron Oxide Nanoparticles in the Prefrontal Cortex, Striatum, and Hippocampus of Rats, Neurotox. Res., 39, 2056, 10.1007/s12640-021-00432-z · DOI
  70. Chen, 2015, Specific detection of CD133-positive tumor cells with iron oxide nanoparticles labeling using noninvasive molecular magnetic resonance imaging, Int. J. Nanomed., 10, 6997
  71. Unterweger, 2017, Non-immunogenic dextran-coated superparamagnetic iron oxide nanoparticles: A biocompatible, size-tunable contrast agent for magnetic resonance imaging, Int. J. Nanomed., 12, 5223, 10.2147/IJN.S138108 · DOI
  72. Hachani, R., Birchall, M.A., Lowdell, M.W., Kasparis, G., Tung, L.D., Manshian, B.B., Soenen, S.J., Gsell, W., Himmelreich, U., and Gharagouzloo, C.A. (2017). Assessing cell-nanoparticle interactions by high content imaging of biocompatible iron oxide nanoparticles as potential contrast agents for magnetic resonance imaging. Sci. Rep., 7. · DOI
  73. Calero, M., Chiappi, M., Lazaro-Carrillo, A., Rodríguez, M.J., Chichón, F.J., Crosbie-Staunton, K., Prina-Mello, A., Volkov, Y., Villanueva, A., and Carrascosa, J.L. (2015). Characterization of interaction of magnetic nanoparticles with breast cancer cells. J. Nanobiotechnol., 13. · DOI
  74. Coricovac, D.E., Moacă, E.A., Pinzaru, I., Cîtu, C., Soica, C., Mihali, C.V., Păcurariu, C., Tutelyan, V.A., Tsatsakis, A., and Dehelean, C.A. (2017). Biocompatible Colloidal Suspensions Based on Magnetic Iron Oxide Nanoparticles: Synthesis, Characterization and Toxicological Profile. Front. Pharmacol., 8. · DOI
  75. Neuwelt, 2007, The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: A pilot study, Neurosurgery, 60, 601, 10.1227/01.NEU.0000255350.71700.37 · DOI · Paper page
  76. Landry, 2005, Pharmacokinetic Study of Ferumoxytol: A New Iron Replacement Therapy in Normal Subjects and Hemodialysis Patients, Am. J. Nephrol., 25, 400, 10.1159/000087212 · DOI
  77. Ersoy, 2007, Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis, J. Magn. Reson. Imaging, 26, 1190, 10.1002/jmri.21135 · DOI
  78. Uchiyama, 2015, Ultrasmall cationic superparamagnetic iron oxide nanoparticles as nontoxic and efficient MRI contrast agent and magnetic-targeting tool, Int. J. Nanomed., 10, 4731
  79. Ali, 2020, Efficient Labeling Of Mesenchymal Stem Cells For High Sensitivity Long-Term MRI Monitoring In Live Mice Brains, Int. J. Nanomed., 15, 97, 10.2147/IJN.S211205 · DOI
  80. Wu, 2022, Ultrasmall iron oxide nanoparticles cause significant toxicity by specifically inducing acute oxidative stress to multiple organs, Part. Fibre Toxicol., 19, 24, 10.1186/s12989-022-00465-y · DOI
  81. Kenzaoui, 2012, Evaluation of uptake and transport of ultrasmall superparamagnetic iron oxide nanoparticles by human brain-derived endothelial cells, Nanomedicine, 7, 39, 10.2217/nnm.11.85 · DOI
  82. Petters, 2016, Lysosomal iron liberation is responsible for the vulnerability of brain microglial cells to iron oxide nanoparticles: Comparison with neurons and astrocytes, Nanotoxicology, 10, 332, 10.3109/17435390.2015.1071445 · DOI · Paper page
  83. Bourrinet, 2006, Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent, Investig. Radiol., 41, 313, 10.1097/01.rli.0000197669.80475.dd · DOI
  84. Zou, 2015, Iron nanoparticles significantly affect the in vitro and in vivo expression of Id genes, Chem. Res. Toxicol., 28, 373, 10.1021/tx500333q · DOI
  85. Královec, K., Melounková, L., Slováková, M., Mannová, N., Sedlák, M., Bartáček, J., and Havelek, R. (2020). Disruption of Cell Adhesion and Cytoskeletal Networks by Thiol-Functionalized Silica-Coated Iron Oxide Nanoparticles. Int. J. Mol. Sci., 21. · DOI
  86. Mai, 2017, Magnetic nanoparticles: Reactive oxygen species generation and potential therapeutic applications, J. Nanoparticle Res., 19, 253, 10.1007/s11051-017-3943-2 · DOI
  87. Ahamed, 2012, Selective killing of cancer cells by iron oxide nanoparticles mediated through reactive oxygen species via p53 pathway, J. Nanoparticle Res., 15, 1225, 10.1007/s11051-012-1225-6 · DOI
  88. Shi, Y., Wang, J., Liu, J., Lin, G., Xie, F., Pang, X., Pei, Y., Cheng, Y., Zhang, Y., and Lin, Z. (2020). Oxidative stress-driven DR5 upregulation restores TRAIL/Apo2L sensitivity induced by iron oxide nanoparticles in colorectal cancer. Biomaterials, 233. · DOI
  89. Shokrollahi, 2023, Evaluation of the effect of iron oxide nanoparticles functionalized by glucose and conjugated with coumarin (Fe3O4@Glu-Coumarin NPs) on the expression of CASP8, CASP9, p53, mTOR1, and MAPK1 genes in liver cancer cell line, Gene Rep., 33, 101818, 10.1016/j.genrep.2023.101818 · DOI
  90. Kanda, 2016, Gadolinium deposition in the brain, Magn. Reson. Imaging, 34, 1346, 10.1016/j.mri.2016.08.024 · DOI
  91. Habermeyer, J., Boyken, J., Harrer, J., Canneva, F., Ratz, V., Moceri, S., Admard, J., Casadei, N., Jost, G., and Bäuerle, T. (2020). Comprehensive phenotyping revealed transient startle response reduction and histopathological gadolinium localization to perineuronal nets after gadodiamide administration in rats. Sci. Rep., 10. · DOI
  92. Irrsack, 2023, Local Administrations of Iron Oxide Nanoparticles in the Prefrontal Cortex and Caudate Putamen of Rats Do Not Compromise Working Memory and Motor Activity, Neurotox. Res., 42, 6, 10.1007/s12640-023-00684-x · DOI
  93. Taboada, 2007, Relaxometric and Magnetic Characterization of Ultrasmall Iron Oxide Nanoparticles with High Magnetization. Evaluation as Potential T1 Magnetic Resonance Imaging Contrast Agents for Molecular Imaging, Langmuir, 23, 4583, 10.1021/la063415s · DOI
  94. Xiao, 2016, MRI contrast agents: Classification and application (Review), Int. J. Mol. Med., 38, 1319, 10.3892/ijmm.2016.2744 · DOI
  95. Edelman, 2024, Dark Blood Contrast-Enhanced Brain MRI Using Echo-uT(1)RESS, J. Magn. Reson. Imaging, 60, 789, 10.1002/jmri.29124 · DOI
  96. Tao, C., Zheng, Q., An, L., He, M., Lin, J., Tian, Q., and Yang, S. (2019). T₁-Weight Magnetic Resonance Imaging Performances of Iron Oxide Nanoparticles Modified with a Natural Protein Macromolecule and an Artificial Macromolecule. Nanomaterials, 9. · DOI
  97. Wei, 2021, Single-nanometer iron oxide nanoparticles as tissue-permeable MRI contrast agents, Proc. Natl. Acad. Sci. USA, 118, e2102340118, 10.1073/pnas.2102340118 · DOI
  98. Yang, L., Afshari, M.J., Ge, J., Kou, D., Chen, L., Zhou, D., Li, C., Wu, S., Zhang, L., and Zeng, J. (2022). Functionalized Ultrasmall Iron Oxide Nanoparticles for T(1)-Weighted Magnetic Resonance Imaging of Tumor Hypoxia. Molecules, 27. · DOI
  99. Christoforidis, 2009, High resolution ultra high field magnetic resonance imaging of glioma microvascularity and hypoxia using ultra-small particles of iron oxide, Investig. Radiol., 44, 375, 10.1097/RLI.0b013e3181a8afea · DOI
  100. Toth, 2017, Current and potential imaging applications of ferumoxytol for magnetic resonance imaging, Kidney Int., 92, 47, 10.1016/j.kint.2016.12.037 · DOI · Paper page
  101. Rad, 2007, Quantification of superparamagnetic iron oxide (SPIO)-labeled cells using MRI, J. Magn. Reson. Imaging, 26, 366, 10.1002/jmri.20978 · DOI
  102. Zhang, 2009, Superparamagnetic iron oxide nanoparticle-labeled cells as an effective vehicle for tracking the GFP gene marker using magnetic resonance imaging, Cytotherapy, 11, 43, 10.1080/14653240802420243 · DOI
  103. Kratz, 2016, Labeling of mesenchymal stem cells for MRI with single-cell sensitivity, Int. J. Nanomed., 11, 1517
  104. Jarzyna, 2012, Tumor angiogenesis phenotyping by nanoparticle-facilitated magnetic resonance and near-infrared fluorescence molecular imaging, Neoplasia, 14, 964, 10.1593/neo.121148 · DOI
  105. Melemenidis, 2015, Molecular Magnetic Resonance Imaging of Angiogenesis In Vivo using Polyvalent Cyclic RGD-Iron Oxide Microparticle Conjugates, Theranostics, 5, 515, 10.7150/thno.10319 · DOI
  106. Daneman, R., and Prat, A. (2015). The blood-brain barrier. Cold Spring Harb. Perspect. Biol., 7. · DOI · Paper page
  107. Aksenov, D.P., and Doubovikov, E.D. (2025). Diffusion constraints in neuroprotection: Implications for clinical trials. Front. Pharmacol., 16. · DOI
  108. Enteshari Najafabadi, R., Kazemipour, N., Esmaeili, A., Beheshti, S., and Nazifi, S. (2018). Using superparamagnetic iron oxide nanoparticles to enhance bioavailability of quercetin in the intact rat brain. BMC Pharmacol. Toxicol., 19. · DOI
  109. Shi, 2016, Optimizing superparamagnetic iron oxide nanoparticles as drug carriers using an in vitro blood-brain barrier model, Int. J. Nanomed., 11, 5371, 10.2147/IJN.S108333 · DOI
  110. Shevtsov, 2014, Superparamagnetic iron oxide nanoparticles conjugated with epidermal growth factor (SPION-EGF) for targeting brain tumors, Int. J. Nanomed., 9, 273, 10.2147/IJN.S55118 · DOI
  111. Salehnia, 2019, Synthesis and characterisation of iron oxide nanoparticles conjugated with epidermal growth factor receptor (EGFR) monoclonal antibody as MRI contrast agent for cancer detection, IET Nanobiotechnol., 13, 400, 10.1049/iet-nbt.2018.5285 · DOI
  112. Shevtsov, 2014, Tumor targeting using magnetic nanoparticle Hsp70 conjugate in a model of C6 glioma, Neuro Oncol., 16, 38, 10.1093/neuonc/not141 · DOI
  113. Bach, 2004, Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells, Protein Eng. Des. Sel., 17, 433, 10.1093/protein/gzh055 · DOI
  114. Wu, 2018, Magnetic resonance imaging of tumor angiogenesis using dual-targeting RGD10-NGR9 ultrasmall superparamagnetic iron oxide nanoparticles, Clin. Transl. Oncol., 20, 599, 10.1007/s12094-017-1753-8 · DOI
  115. Neshastehriz, 2022, Folate functionalized gold-coated magnetic nanoparticles effect in combined electroporation and radiation treatment of HPV-positive oropharyngeal cancer, Med. Oncol., 39, 196, 10.1007/s12032-022-01780-2 · DOI
  116. Liang, 2016, Doxorubicin-modified magnetic nanoparticles as a drug delivery system for magnetic resonance imaging-monitoring magnet-enhancing tumor chemotherapy, Int. J. Nanomed., 11, 2021
  117. Patel, 2023, Development of a Personalised Device for Systemic Magnetic Drug Targeting to Brain Tumours, Nanotheranostics, 7, 102, 10.7150/ntno.76559 · DOI
  118. Sun, 2008, Tumor-targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles, Nanomedicine, 3, 495, 10.2217/17435889.3.4.495 · DOI
  119. Dutta, 2007, Adsorbed proteins influence the biological activity and molecular targeting of nanomaterials, Toxicol. Sci., 100, 303, 10.1093/toxsci/kfm217 · DOI
  120. Moghimi, 2001, Long-circulating and target-specific nanoparticles: Theory to practice, Pharmacol. Rev., 53, 283, 10.1016/S0031-6997(24)01494-7 · DOI
  121. Nagayama, 2007, Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics, Int. J. Pharm., 342, 215, 10.1016/j.ijpharm.2007.04.036 · DOI
  122. Camner, 2002, Experimental and calculated parameters on particle phagocytosis by alveolar macrophages, J. Appl. Physiol., 92, 2608, 10.1152/japplphysiol.01067.2001 · DOI
  123. Chen, 2010, Reducing non-specific binding and uptake of nanoparticles and improving cell targeting with an antifouling PEO-b-PgammaMPS copolymer coating, Biomaterials, 31, 5397, 10.1016/j.biomaterials.2010.03.036 · DOI
  124. Foy, 2010, Optical imaging and magnetic field targeting of magnetic nanoparticles in tumors, ACS Nano, 4, 5217, 10.1021/nn101427t · DOI
  125. Aggarwal, 2009, Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy, Adv. Drug Deliv. Rev., 61, 428, 10.1016/j.addr.2009.03.009 · DOI · Paper page
  126. Ikeda, 2018, Activatable fluorescence imaging of macrophages in atherosclerotic plaques using iron oxide nanoparticles conjugated with indocyanine green, Atherosclerosis, 275, 1, 10.1016/j.atherosclerosis.2018.05.028 · DOI
  127. Wang, 2018, Iron oxide-carbon core-shell nanoparticles for dual-modal imaging-guided photothermal therapy, J. Control. Release, 289, 70, 10.1016/j.jconrel.2018.09.022 · DOI
  128. Gneveckow, 2004, Description and characterization of the novel hyperthermia- and thermoablation-system for clinical magnetic fluid hyperthermia, Med. Phys., 31, 1444, 10.1118/1.1748629 · DOI
  129. Pu, 2000, Apoptosis induced by hyperthermia in human glioblastoma cell line and murine glioblastoma, Chin. J. Cancer Res., 12, 257, 10.1007/BF02983501 · DOI
  130. Rothe, 2007, Intracranial Thermotherapy using Magnetic Nanoparticles Combined with External Beam Radiotherapy: Results of a Feasibility Study on Patients with Glioblastoma Multiforme, J. Neuro-Oncol., 81, 53, 10.1007/s11060-006-9195-0 · DOI
  131. Usov, 2019, Iron Oxide Nanoparticles for Magnetic Hyperthermia, SPIN, 09, 1940001, 10.1142/S2010324719400010 · DOI
  132. Etheridge, 2014, Accounting for biological aggregation in heating and imaging of magnetic nanoparticles, Technology, 02, 214, 10.1142/S2339547814500198 · DOI · Paper page
  133. Nemati, 2016, Enhanced Magnetic Hyperthermia in Iron Oxide Nano-Octopods: Size and Anisotropy Effects, J. Phys. Chem. C, 120, 8370, 10.1021/acs.jpcc.6b01426 · DOI
  134. Pericchi, 2015, Optimization of synthesis and peptization steps to obtain iron oxide nanoparticles with high energy dissipation rates, J. Magn. Magn. Mater., 394, 361, 10.1016/j.jmmm.2015.06.076 · DOI
  135. Nemati, 2018, Improving the Heating Efficiency of Iron Oxide Nanoparticles by Tuning Their Shape and Size, J. Phys. Chem. C, 122, 2367, 10.1021/acs.jpcc.7b10528 · DOI
  136. Singh, 2023, A threefold increase in SAR performance for magnetic hyperthermia by compositional tuning in zinc-substituted iron oxide superparamagnetic nanoparticles with superior biocompatibility, J. Alloys Compd., 968, 171868, 10.1016/j.jallcom.2023.171868 · DOI
  137. Myrovali, E., Maniotis, N., Makridis, A., Terzopoulou, A., Ntomprougkidis, V., Simeonidis, K., Sakellari, D., Kalogirou, O., Samaras, T., and Salikhov, R. (2016). Arrangement at the nanoscale: Effect on magnetic particle hyperthermia. Sci. Rep., 6. · DOI
  138. Mehdaoui, 2010, Large specific absorption rates in the magnetic hyperthermia properties of metallic iron nanocubes, J. Magn. Magn. Mater., 322, L49, 10.1016/j.jmmm.2010.05.012 · DOI
  139. Fatima, H., Charinpanitkul, T., and Kim, K.-S. (2021). Fundamentals to Apply Magnetic Nanoparticles for Hyperthermia Therapy. Nanomaterials, 11. · DOI
  140. Kahil, H., Faramawy, A., El-Sayed, H., and Abdel-Sattar, A. (2021). Magnetic Properties and SAR for Gadolinium-Doped Iron Oxide Nanoparticles Prepared by Hydrothermal Method. Crystals, 11. · DOI
  141. Balakrishnan, 2020, Exploiting Unique Alignment of Cobalt Ferrite Nanoparticles, Mild Hyperthermia, and Controlled Intrinsic Cobalt Toxicity for Cancer Therapy, Adv. Mater., 32, e2003712, 10.1002/adma.202003712 · DOI
  142. Khurshid, 2015, Anisotropy effects in magnetic hyperthermia: A comparison between spherical and cubic exchange-coupled FeO/Fe3O4 nanoparticles, J. Appl. Phys., 117, 17A337, 10.1063/1.4919250 · DOI
  143. Thanh, 2025, Iron oxide nanoparticles synthesized by coprecipitation method: Impacts of zinc doping and surface functionalization by polyvinylpyrrolidone on the magnetic properties and heating efficiency, Ceram. Int., 51, 1448, 10.1016/j.ceramint.2024.11.118 · DOI
  144. Oroskhani, N., Amini, S.M., Shirvalilou, S., Khodaie, M., and Mahdavi, S.R. (2024). Anti-Proliferative Activity of Poloxamer Cobalt Ferrite Nanoparticles against Human Prostate Cancer (DU-145) Cells: In-Vitro Study. IET Nanobiotechnol., 2024. · DOI
  145. Yang, Y., Wang, F., Zheng, K., Deng, L., Yang, L., Zhang, N., Xu, C., Ran, H., Wang, Z., and Wang, Z. (2017). Injectable PLGA/Fe3O4 implants carrying cisplatin for synergistic magnetic hyperthermal ablation of rabbit VX2 tumor. PLoS ONE, 12. · DOI
  146. Shirvalilou, 2021, Magnetic Hyperthermia as an adjuvant cancer therapy in combination with radiotherapy versus radiotherapy alone for recurrent/progressive glioblastoma: A systematic review, J. Neuro-Oncol., 152, 419, 10.1007/s11060-021-03729-3 · DOI
  147. Kampinga, 2001, Hyperthermic radiosensitization: Mode of action and clinical relevance, Int. J. Radiat. Biol., 77, 399, 10.1080/09553000010024687 · DOI
  148. Krawczyk, 2011, Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition, Proc. Natl. Acad. Sci. USA, 108, 9851, 10.1073/pnas.1101053108 · DOI
  149. Karakatsanis, 2017, Superparamagnetic iron oxide nanoparticles as the sole method for sentinel node biopsy detection in patients with breast cancer, Br. J. Surg., 104, 1675, 10.1002/bjs.10606 · DOI
  150. Lee, D., Sohn, J., and Kirichenko, A. (2022). Quantifying Liver Heterogeneity via R2*-MRI with Super-Paramagnetic Iron Oxide Nanoparticles (SPION) to Characterize Liver Function and Tumor. Cancers, 14. · DOI
  151. Colombo, 2012, Biological applications of magnetic nanoparticles, Chem. Soc. Rev., 41, 4306, 10.1039/c2cs15337h · DOI
  152. Leiner, 2003, Multicenter phase-II trial of safety and efficacy of NC100150 for steady-state contrast-enhanced peripheral magnetic resonance angiography, Eur. Radiol., 13, 1620, 10.1007/s00330-002-1791-6 · DOI
  153. Weishaupt, 2000, Equilibrium-Phase MR Angiography of the Aortoiliac and Renal Arteries Using a Blood Pool Contrast Agent, Am. J. Roentgenol., 175, 189, 10.2214/ajr.175.1.1750189 · DOI
  154. Lassalle, 2017, Magnetic iron oxide nanoparticles as novel and efficient tools for atherosclerosis diagnosis, Biomed. Pharmacother., 93, 1098, 10.1016/j.biopha.2017.07.012 · DOI
  155. Taupitz, 2004, Phase I Clinical Evaluation of Citrate-coated Monocrystalline Very Small Superparamagnetic Iron Oxide Particles as a New Contrast Medium for Magnetic Resonance Imaging, Investig. Radiol., 39, 394, 10.1097/01.rli.0000129472.45832.b0 · DOI
  156. Wagner, 2011, Coronary MR angiography using citrate-coated very small superparamagnetic iron oxide particles as blood-pool contrast agent: Initial experience in humans, J. Magn. Reson. Imaging, 34, 816, 10.1002/jmri.22683 · DOI
  157. Teshome, 2016, Use of a Magnetic Tracer for Sentinel Lymph Node Detection in Early-Stage Breast Cancer Patients: A Meta-analysis, Ann. Surg. Oncol., 23, 1508, 10.1245/s10434-016-5135-1 · DOI
  158. Engberink, 2010, Magnetic Resonance Imaging of Monocytes Labeled with Ultrasmall Superparamagnetic Particles of Iron Oxide Using Magnetoelectroporation in an Animal Model of Multiple Sclerosis, Mol. Imaging, 9, 268, 10.2310/7290.2010.00016 · DOI
  159. Blumenstein, 2021, Newer formulations of intravenous iron: A review of their chemistry and key safety aspects–hypersensitivity, hypophosphatemia, and cardiovascular safety, Expert. Opin. Drug Saf., 20, 757, 10.1080/14740338.2021.1912010 · DOI
  160. Tassa, 2011, Dextran-Coated Iron Oxide Nanoparticles: A Versatile Platform for Targeted Molecular Imaging, Molecular Diagnostics, and Therapy, Acc. Chem. Res., 44, 842, 10.1021/ar200084x · DOI · Paper page
  161. Jin, 2014, Superparamagnetic iron oxide nanoparticles for MR imaging and therapy: Design considerations and clinical applications, Curr. Opin. Pharmacol., 18, 18, 10.1016/j.coph.2014.08.002 · DOI · Paper page
  162. Ahmad, 2015, Magnetic nanoparticles: In vivo cancer diagnosis and therapy, Int. J. Pharm., 493, 313, 10.1016/j.ijpharm.2015.07.059 · DOI
  163. Nardecchia, S., Sánchez-Moreno, P., de Vicente, J., Marchal, J.A., and Boulaiz, H. (2019). Clinical Trials of Thermosensitive Nanomaterials: An Overview. Nanomaterials, 9. · DOI
  164. Lapusan, 2024, Advancing MRI with magnetic nanoparticles: A comprehensive review of translational research and clinical trials, Nanoscale Adv., 6, 2234, 10.1039/D3NA01064C · DOI
  165. Egea-Benavente, D., Ovejero, J.G., Morales, M.D.P., and Barber, D.F. (2021). Understanding MNPs Behaviour in Response to AMF in Biological Milieus and the Effects at the Cellular Level: Implications for a Rational Design That Drives Magnetic Hyperthermia Therapy toward Clinical Implementation. Cancers, 13. · DOI
  166. Grauer, 2016, RTHP-22. inflammatory response after modified nanotherm and radiotherapy of recurrent glioblastoma, Jpn. Soc. Neuro-Oncol., 18, vi178, 10.1093/neuonc/now212.748 · DOI
  167. Marcus, M., Smith, A., Maswadeh, A., Shemesh, Z., Zak, I., Motiei, M., Schori, H., Margel, S., Sharoni, A., and Shefi, O. (2018). Magnetic Targeting of Growth Factors Using Iron Oxide Nanoparticles. Nanomaterials, 8. · DOI
  168. Yellen, 2005, Targeted drug delivery to magnetic implants for therapeutic applications, J. Magn. Magn. Mater., 293, 647, 10.1016/j.jmmm.2005.01.083 · DOI
  169. Doubovikov, 2024, Brain Tissue Oxygen Dynamics Under Localised Hypoxia in the Awake State and the Physical Neuroprotective Effects of General Anaesthesia, Oxygen Transport to Tissue XLV, Volume 1463, 35, 10.1007/978-3-031-67458-7_6 · DOI
  170. Pislaru, 2006, Magnetic forces enable rapid endothelialization of synthetic vascular grafts, Circulation, 114, I314, 10.1161/CIRCULATIONAHA.105.001446 · DOI
  171. Pislaru, 2006, Magnetically Targeted Endothelial Cell Localization in Stented Vessels, J. Am. Coll. Cardiol., 48, 1839, 10.1016/j.jacc.2006.06.069 · DOI
  172. Consigny, 1999, Use of Endothelial Cells Containing Superparamagnetic Microspheres to Improve Endothelial Cell Delivery to Arterial Surfaces after Angioplasty, J. Vasc. Interv. Radiol., 10, 155, 10.1016/S1051-0443(99)70458-6 · DOI
  173. Westphal, 2003, A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma, Neuro Oncol., 5, 79, 10.1093/neuonc/5.2.79 · DOI

Cited by

Sorted by citations

See all 23

Metadata

Authors
Varalli, L., Berlet, R., Abenojar, E., McDaid, J., Gascoigne, D. A., Bailes, J., & Aksenov, D. P.
Venue
Pharmaceutics
Publisher
MDPI AG
Published
2025-04-09
Volume
17
Issue
4
Pages
499
ISSN
1999-4923
DOI
10.3390/pharmaceutics17040499
PMC
PMC12030199
Cited by
23
References
8
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review